ArticlePloS one2016
Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Literature Review on the Use of Dried Biofluid Microsampling in Patients With Kidney Disease.Journal of clinical laboratory analysis · 2024Pooled it
- Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial.British journal of clinical pharmacology · 2020Trial
- homeRNA Just Dropped! Streamlining Remote Blood Collection and RNA Stabilization for Smaller Sample Volumes with homeRNAdrop.bioRxiv : the preprint server for biology · 2026Article
- Strategies to Overcome Hematocrit and Volume Bias in Dried Blood Spot Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Revisiting Thyroglobulin Measurement: Current Methods and Future Perspectives Using Dried Blood Spot Sampling for Enhanced Clinical Practice.Metabolites · 2025Review
- Feasibility of blood self-sampling with HemaSpot HF for Anti-Clostridium tetani Toxin IgG detection.Scientific reports · 2025Article
- Multiplex quantification of endocrine proteins in volumetric dried blood spots.Clinical proteomics · 2025Article
- Dried Blood Spot Sampling for Monitoring Children With Immune-Mediated Glomerulopathies and After Kidney Transplantation.Kidney international reports · 2024Article
- Towards genomic-Newborn Screening: Technical feasibility of Exome Sequencing starting from dried blood spots.Molecular genetics and metabolism reports · 2024Article
- Proteome profiling of home-sampled dried blood spots reveals proteins of SARS-CoV-2 infections.Communications medicine · 2024Article
- Self-Powered Microfluidics for Point-of-Care Solutions: From Sampling to Detection of Proteins and Nucleic Acids.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Serum Creatinine and Tacrolimus Assessment With VAMS Finger-Prick Microsampling: A Diagnostic Test Study.Kidney medicine · 2023Article
- Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice.Journal of clinical medicine · 2022Article
- Article
- Validation of whole genome sequencing from dried blood spots.BMC medical genomics · 2021Article
- Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients.Frontiers in pharmacology · 2021Review
- Healthcare costs and productivity losses associated with county-based home-care service for sick children in Sweden.Scandinavian journal of caring sciences · 2020Observational
- Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders.International journal of neonatal screening · 2020Review
- Improved Dried Blood Spot-Based Metabolomics: A Targeted, Broad-Spectrum, Single-Injection Method.Metabolites · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dried blood spot (DBS) sampling for the purpose of therapeutic drug monitoring can be an attractive alternative for conventional blood sampling, especially in children. This study aimed to compare all costs involved in conventional sampling versus DBS home sampling in two pediatric populations: renal transplant patients and hemato-oncology patients. Total costs were computed from a societal perspective by adding up healthcare cost, patient related costs and costs related to loss of productivity of the caregiver. Switching to DBS home sampling was associated with a cost reduction of 43% for hemato-oncology patients (€277 to €158) and 61% for nephrology patients (€259 to €102) from a societal perspective (total costs) per blood draw. From a healthcare perspective, costs reduced with 7% for hemato-oncology patients and with 21% for nephrology patients. Total savings depend on the number of hospital visits that can be avoided by using home sampling instead of conventional sampling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.